Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05639400

Thoraflex Hybrid and Relay Extension Post-Approval Study

The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting the aortic arch and descending aorta with or without involvement of the ascending aorta.

Patients who undergo treatment with the Thoraflex Hybrid device with or without extension with a RelayPro NBS stent-graft will be eligible for enrolment and study activities and follow-up regime will follow standard care at each participating site.

Participant involvement in the study will last for a total of 10 years from the point at which the Thoraflex Hybrid device is placed.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Thoracic Diseases Acute Aortic Syndrome Aneurysm Aortic Aneurysm Aortic Aneurysm, Thoracic Aortic Diseases Aortic Dissection Cardiovascular Diseases Dissection, Blood Vessel Dissection, Thoracic Aorta Respiratory Tract Diseases Thoracic Aortic Aneurysm Thoracic Aortic Dissection Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Paracelsus Medical University, Salzburg, Austria

Loading trial locations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient is aged 18 years or older on date of consent. Patient is willing and able to comply with all study procedures and visits. Patient or their next of kin (NOK)/legally designated representative (LDR) has given written informed consent to participate in the study.

Patient will undergo treatment with a Thoraflex Hybrid device. If a patient requires an extension procedure due to the extent of aortic disease, a RelayPro NBS Stent-graft should be placed inside the distal end of the previously placed Thoraflex Hybrid device via a retrograde approach. This may be part of the same or a two-stage procedure.

Exclusion criteria

  • Patient has any medical, social, or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure.

Treatment and study plan

Thoraflex Hybrid

Device

Thoraflex Hybrid is designed for the open surgical repair of aneurysms and/or dissections in the aortic arch and descending aorta with or without involvement of the ascending aorta. There are two types of Thoraflex Hybrid implants, namely the Plexus 4 and the Ante-Flo versions. Each patient receives one Thoraflex Hybrid device (either the Plexus 4 or Ante-Flo).

RelayPro NBS

Device

The RelayPro NBS Thoracic Stent-Graft System is an endovascular device intended for treatment of thoracic aortic pathologies such as aneurysms, pseudoaneurysms, dissections, penetrating ulcers and intramural hematoma.

Primary outcomes

  1. Primary Safety Endpoint is a composite of the following:

    Time frame: The primary safety endpoint will be measured at one-year after the index procedure and again at least 8 months after the (first) extension procedure.

    • Permanent disabling stroke (mRS >2 and an increase in at least one mRS category from the individual's pre-stroke baseline, occurring within 30 days of either index procedure or extension and present at 1-year follow-up)* Note: If a subject dies prior to 1-year follow-up, their last recorded mRS will be considered their final score
    • Grade 3 spinal cord ischemia (SVS reporting standards) occurring within 30 days of either index procedure or extension
    • All-cause mortality (within 1 year of either procedure)

    (*Per VARC-3, disability assessment using the mRS should be performed between 30 and 90 days after a neurological event with 90 days being optimal. An increased mRS score by itself and in the absence of a neurological event does not constitute stroke.)

  2. Primary Effectiveness Endpoint: Treatment Success

    Time frame: The primary effectiveness endpoint will be measured at one-year after the index procedure and again at least 8 months after the (first) extension procedure.

    Defined as device technical success (of either procedure) with absence of the following at 1-year:

    • Lesion-related mortality (defined as all deaths occurring within 30 days of, or, prior to discharge, from either the index procedure or the extension procedure or any revision procedures to treat the original lesion(s) and any other deaths adjudicated by Clinical Events Committee as related or probably related to the lesion(s))
    • Aortic rupture in the treated segment
    • Lesion expansion (≥5mm increase from measurement at discharge/within 30 days)
    • Secondary intervention to address the following:
    • Stent graft-induced aortic wall injury (SAWI)
    • Fistula
    • Type I or III endoleak (see definitions)
    • Migration
    • Loss of Patency
    • Thromboembolic events
    • Failure of integrity

Secondary outcomes

  1. Secondary Safety Endpoints, Absence of the following

    Time frame: The secondary endpoints will be measured at each follow-up timepoint from discharge/30 days through to 10 years.

    • All-cause mortality, and
    • Lesion-related mortality (defined as all deaths occurring within 30 days of, or, prior to discharge, from either the index procedure or the extension procedure or any revision procedures to treat the original lesion(s) and any other deaths adjudicated by Clinical Events Committee as related or probably related to the lesion(s))
    • All/any paraplegia/paraparesis defined as SCI (SVS grades 1 to 3)
    • Any stroke (excluding TIA)
    • Incidence of Myocardial Infarction
    • Incidence of Respiratory Failure
    • Incidence of Renal Failure
    • Incidence of Bowel Ischemia

  2. Secondary effectiveness endpoints will be reported

    Time frame: The secondary endpoints will be measured at each follow-up timepoint from discharge/30 days through to 10 years.

    • Any aortic rupture (treated and untreated segments)
    • Aortic remodeling in the treated segment(s)
    • New dissections
    • Proximal and distal extension of dissections
    • Any false lumen perfusion (specifying location and if intentional or not)
    • Fistula formation
    • All endoleaks
    • Device migration (measure both >5mm from position at discharge/within 30 days, and >10 mm from position at discharge/within 30 days, and requiring secondary intervention)
    • Device integrity issues (e.g., stent fracture)
    • All thromboembolic events
    • Pseudoaneurysms (device-related)
    • Secondary Interventions
    • Graft patency (loss of patency will be defined as an opening of <50% due to, for example, occlusion, stenosis, kinking)

Sponsors and collaborators

Lead sponsor

Vascutek Ltd.

Industry

Collaborators

  • Bolton Medical

Registry information

Acronym: EXTEND

Important dates

Study start
2023
Primary completion
2035
Study completion
2036
First posted
Dec 6, 2022
Registry last updated
Feb 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.